Metformin Hydrochloride Lyrus Life Sciences (Metformin Hydrochloride)

Metformin Hydrochloride is a biguanide antidiabetic that improves glycemic control in several glucose‑related conditions.

• Type 2 diabetes mellitus: improves fasting and post‑prandial glucose, reducing HbA1c.
• Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes.
• Gestational diabetes mellitus (when indicated): assists in achieving target glucose levels during pregnancy.

• Metformin Hydrochloride primarily inhibits hepatic gluconeogenesis by activating AMP‑activated protein kinase (AMPK), which reduces hepatic glucose output. It also enhances peripheral insulin sensitivity by increasing glucose uptake in muscle and adipose tissue and modestly decreases intestinal glucose absorption, collectively lowering plasma glucose concentrations without stimulating insulin secretion.

Metformin Hydrochloride may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite.
• Diarrhea: often mild to moderate and transient.
• Metallic taste: a temporary alteration in taste perception.
• Flatulence: increased intestinal gas.
• Weight loss: modest reduction in body weight.
• Vitamin B12 deficiency: gradual decline with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic complication.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: marked elevation of liver enzymes.
• Hypoglycemia: when combined with other glucose‑lowering agents.
• Anemia: due to reduced red blood cell production.
• Pancreatitis: inflammation of the pancreas.

When prescribing Metformin Hydrochloride, clinicians should observe several safety considerations.

• Renal function: assess eGFR before initiation and periodically during therapy.
• Hepatic function: avoid use in patients with severe liver disease.
• Lactic acidosis risk: discontinue if patient develops hypoxia, sepsis, or acute heart failure.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Vitamin B12 status: monitor long‑term therapy for possible deficiency.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure; stop metformin before and resume after renal function normalizes.
• Alcohol excess: increases risk of lactic acidosis.
• Cimetidine: can raise metformin plasma concentrations.
• Carbamazepine: may reduce metformin efficacy.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Diuretics (especially thiazides): may affect glucose control.
• Warfarin: monitor INR as metformin may alter anticoagulant effect.